Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MAZE

Maze Therapeutics Inc

Feb 06 • 04:00PM ET

45.03

+1.08 2.46 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF IBB IWN XPH SCHA VTWO IWC IHE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.25	Insider Own	45.74%	Shs Outstand	48.08M	Perf Week	3.33%
Market Cap	2.17B	Forward P/E	-	EPS next Y	-3.14	Insider Trans	-1.12%	Shs Float	26.11M	Perf Month	11.54%
Enterprise Value	1.81B	PEG	-	EPS next Q	-0.71	Inst Own	43.84%	Short Float	9.88%	Perf Quarter	48.76%
Income	-101.46M	P/S	-	EPS this Y	-350.27%	Inst Trans	11.85%	Short Ratio	5.70	Perf Half Y	238.06%
Sales	0.00M	P/B	5.71	EPS next Y	-0.33%	ROA	-28.15%	Short Interest	2.58M	Perf YTD	8.69%
Book/sh	7.89	P/C	5.64	EPS next 5Y	-	ROE	-36.13%	52W High	49.25 -8.57%	Perf Year	250.97%
Cash/sh	7.98	P/FCF	-	EPS past 3/5Y	- -	ROIC	-25.44%	52W Low	6.71 571.09%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.31% 7.47%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	3.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.70	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.42	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	17.70	EPS Q/Q	-1029.60%	SMA20	2.86%	Beta	4.42	Target Price	51.12
Payout	-	Debt/Eq	0.06	Sales Q/Q	-100.00%	SMA50	8.49%	Rel Volume	1.47	Prev Close	43.95
Employees	125	LT Debt/Eq	0.05	Earnings	Nov 06 AMC	SMA200	85.08%	Avg Volume	452.63K	Price	45.03
IPO	Jan 31, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.81% -	Trades		Volume	663,464	Change	2.46%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Initiated	Wells Fargo	Overweight	$55
Nov-14-25	Initiated	Raymond James	Outperform
Sep-02-25	Initiated	BTIG Research	Buy	$30
Jul-23-25	Initiated	H.C. Wainwright	Buy	$34
Jul-08-25	Initiated	Wedbush	Outperform	$17

Feb-04-26 07:00AM	Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-05-26 07:00AM	Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-06-25 04:01PM	Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
07:00AM	Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week (GlobeNewswire)
Nov-04-25 07:00AM	Maze Therapeutics to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
04:43PM	Loading…
Oct-28-25 04:43PM	Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease (CNBC TV)
Oct-06-25 07:00AM	Maze Therapeutics Appoints Industry Veteran Herve Hoppenot as Chairman of the Board of Directors (GlobeNewswire)
Sep-19-25 04:02PM	Maze Therapeutics, Inc. (MAZE): A Bull Case Theory (Insider Monkey)
Sep-17-25 06:22PM	Biotech Breakouts: 3 Stocks With Massive Upside Potential (MarketBeat)
Sep-12-25 07:45AM	Maze reports positive results from Phase I trial of PKU and CKD treatment (Clinical Trials Arena) -6.07%
06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive)
Sep-11-25 09:29AM	Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results (Investor's Business Daily) +54.81%
07:35AM	Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement (GlobeNewswire)
07:30AM	Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) (GlobeNewswire)
Sep-02-25 07:00AM	Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer (GlobeNewswire) +5.73%
04:01PM	Loading…
Aug-12-25 04:01PM	Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Jul-31-25 07:46AM	Venture firm Frazier closes $1.3B fund for early-stage biotech investing (BioPharma Dive)
Jul-10-25 04:05PM	Maze Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-29-25 07:30AM	Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference (GlobeNewswire) +6.01%
May-14-25 04:01PM	Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones (GlobeNewswire) -8.11%
May-13-25 07:30AM	Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Mar-31-25 07:30AM	Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-26-25 05:02PM	Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist (SeekingAlpha) -7.48%
Feb-25-25 04:11PM	Maze Therapeutics receives positive ratings following recent IPO (Investing.com) +10.69%
Feb-10-25 07:09AM	Maze Therapeutics doses first subject in Phase II AKD treatment trial (Clinical Trials Arena)
Feb-07-25 08:00AM	Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (GlobeNewswire)
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
07:30PM	Maze Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bernstein Harold	President, R&D & CMO	Feb 02 '26	Option Exercise	10.42	15,000	156,300	15,000	Feb 04 04:25 PM
Bernstein Harold	President, R&D & CMO	Feb 02 '26	Sale	46.02	15,000	690,334	0	Feb 04 04:25 PM
Bachrodt Amy	SVP, Finance	Feb 02 '26	Option Exercise	10.42	5,000	52,100	17,965	Feb 04 04:23 PM
Bachrodt Amy	SVP, Finance	Feb 02 '26	Sale	46.04	5,000	230,219	12,965	Feb 04 04:23 PM
Dandekar Atul	CSBO	Jan 29 '26	Option Exercise	10.42	7,500	78,150	18,003	Feb 02 04:21 PM
Dandekar Atul	CSBO	Jan 29 '26	Sale	44.27	7,500	331,990	10,503	Feb 02 04:21 PM
Bachrodt Amy	SVP, Finance	Jan 22 '26	Option Exercise	10.42	5,000	52,100	17,965	Jan 26 04:10 PM
Bachrodt Amy	SVP, Finance	Jan 22 '26	Sale	45.52	5,000	227,612	12,965	Jan 26 04:10 PM
SEKAR KATHIRESAN	Former Director	Jan 16 '26	Proposed Sale	40.67	29,772	1,210,937		Jan 16 04:28 PM
Bernstein Harold	President, R&D & CMO	Jan 07 '26	Option Exercise	10.42	25,156	262,126	25,156	Jan 09 04:51 PM
Bernstein Harold	President, R&D & CMO	Jan 07 '26	Sale	40.20	25,156	1,011,299	0	Jan 09 04:51 PM
Sohn Catherine A.	Director	Jan 07 '26	Option Exercise	10.42	26,920	280,506	26,920	Jan 08 04:30 PM
Sohn Catherine A.	Director	Jan 06 '26	Option Exercise	10.42	2,493	25,977	2,493	Jan 08 04:30 PM
Sohn Catherine A.	Director	Jan 07 '26	Sale	39.11	26,920	1,052,785	0	Jan 08 04:30 PM
Sohn Catherine A.	Director	Jan 06 '26	Sale	38.62	2,493	96,270	0	Jan 08 04:30 PM
CATHERINE SOHN	Director	Jan 07 '26	Proposed Sale	39.11	26,920	1,052,785		Jan 07 04:00 PM
CATHERINE SOHN	Director	Jan 06 '26	Proposed Sale	38.62	2,493	96,270		Jan 06 04:36 PM
Bernstein Harold	President, R&D & CMO	Jan 02 '26	Option Exercise	10.42	4,432	46,181	4,432	Jan 06 04:31 PM
Bernstein Harold	President, R&D & CMO	Jan 05 '26	Option Exercise	10.42	412	4,293	412	Jan 06 04:31 PM
Bernstein Harold	President, R&D & CMO	Jan 02 '26	Sale	40.43	4,432	179,188	0	Jan 06 04:31 PM
Bernstein Harold	President, R&D & CMO	Jan 05 '26	Sale	40.00	412	16,480	0	Jan 06 04:31 PM
Bachrodt Amy	SVP, Finance	Jan 02 '26	Option Exercise	10.42	5,000	52,100	17,965	Jan 06 04:30 PM
Bachrodt Amy	SVP, Finance	Jan 02 '26	Sale	39.15	5,000	195,754	12,965	Jan 06 04:30 PM
Dandekar Atul	CSBO	Dec 29 '25	Option Exercise	10.42	72,400	754,408	82,903	Dec 31 04:24 PM
Dandekar Atul	CSBO	Dec 30 '25	Option Exercise	10.42	100	1,042	10,603	Dec 31 04:24 PM
Dandekar Atul	CSBO	Dec 29 '25	Sale	40.56	72,400	2,936,763	10,503	Dec 31 04:24 PM
Dandekar Atul	CSBO	Dec 30 '25	Sale	40.36	100	4,036	10,503	Dec 31 04:24 PM
Bernstein Harold	President, R&D & CMO	Dec 29 '25	Option Exercise	10.42	45,000	468,900	45,000	Dec 31 04:22 PM
Bernstein Harold	President, R&D & CMO	Dec 29 '25	Sale	40.56	45,000	1,825,355	0	Dec 31 04:22 PM
Bachrodt Amy	SVP, Finance	Dec 29 '25	Option Exercise	10.42	10,000	104,200	22,965	Dec 31 04:20 PM
Bachrodt Amy	SVP, Finance	Dec 30 '25	Option Exercise	10.42	5,000	52,100	17,965	Dec 31 04:20 PM
Bachrodt Amy	SVP, Finance	Dec 29 '25	Sale	40.58	10,000	405,766	12,965	Dec 31 04:20 PM
Bachrodt Amy	SVP, Finance	Dec 30 '25	Sale	40.08	5,000	200,407	12,965	Dec 31 04:20 PM
HAROLD BERNSTEIN	Officer	Dec 29 '25	Proposed Sale	42.10	105,000	4,420,500		Dec 29 04:28 PM
ATUL P DANDEKAR	Officer	Dec 29 '25	Proposed Sale	42.10	87,500	3,683,750		Dec 29 04:25 PM
SEKAR KATHIRESAN	Former Board Member	Dec 04 '25	Proposed Sale	42.54	10,000	425,423		Dec 04 04:08 PM
SEKAR KATHIRESAN	Former Board Member	Nov 21 '25	Proposed Sale	35.80	27,500	984,588		Nov 21 04:09 PM
SCHELLER RICHARD H	Director	Sep 15 '25	Sale	22.37	20,744	464,035	0	Sep 16 04:26 PM
RICHARD SCHELLER	Director	Sep 15 '25	Proposed Sale	22.37	20,744	464,035		Sep 15 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MAZE

Maze Therapeutics Inc

Upgrade your FINVIZ experience